Lurasidone in the treatment of schizophrenia: Results of a double ‐blind, placebo‐controlled trial in Asian patients

ConclusionsIn the ITT (but not the mITT) population, treatment with lurasidone was associated with significant improvement in the PANSS total score in patients with schizophrenia. Lurasidone was generally well tolerated with minimal impact on weight and metabolic parameters.

Source: Asia-Pacific Psychiatry - April 3, 2019 Category: Psychiatry Authors: Teruhiko Higuchi, Jun Ishigooka, Masaomi Iyo, Chin ‐Bin Yeh, Esther Gunaseli Ebenezer, Kuei Yu Liang, Jung Sik Lee, Sang Yeol Lee, Shih Ku Lin, Bo‐Hyun Yoon, Masatoshi Nakamura, Katsuhiko Hagi, Takayuki Sato Tags: ORIGINAL ARTICLE Source Type: research